GlassScriptPhysician profile
Susan L Lee
NPI 1265466742
$2,115.01
in general payments reported to CMS, 2019-2025
22 companies · $20.11 in 2025
The $20.11 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $159 · 2022: $718 · 2023: $816 · 2024: $402 · 2025: $20.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $661.17 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $256.11 | 2021-2024 | Breztri, Fasenra, Farxiga |
| Novo Nordisk INC | $194.58 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $189.88 | 2021-2024 | |
| Pfizer INC. | $157.80 | 2022-2024 | |
| Glaxosmithkline, LLC. | $97.88 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $86.71 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $73.88 | 2021-2022 | |
| Lilly USA, LLC | $69.89 | 2023-2024 | Mounjaro |
| Ibsa Pharma INC. | $40.75 | 2023-2024 | Tirosint, Licart, Licart |
| Idorsia Pharmaceuticals US INC | $40.57 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.93 | 2021-2023 | Tradjenta, Jardiance, Synjardy |
| Phathom Pharmaceuticals, INC. | $33.67 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $26.60 | 2022 | |
| Axsome Therapeutics, INC. | $24.17 | 2023 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.06 | 2022 | |
| Emd Serono, INC. | $20.11 | 2025 | |
| Ardelyx, INC. | $20.05 | 2024 | Ibsrela |
| Exeltis, USA INC. | $19.95 | 2023 | Slynd |
| Biohaven Pharmaceutical Holding Company LTD. | $17.95 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.12 | 2022 | |
| Amgen INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.